Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

被引:19
作者
Song, Jehun [1 ]
Kang, Seongmin [1 ]
Choi, Seung Won [1 ]
Seo, Kwang Won [2 ]
Lee, Sunggun [3 ]
So, Min Wook [4 ]
Lim, Doo-Ho [1 ]
机构
[1] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Rheumatol,Dept Internal Med, 877 Bangeojinsunhwan Doro, Ulsan 44033, South Korea
[2] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Pulm & Crit Care Med,Dept Internal Med, Ulsan, South Korea
[3] Inje Univ, Haeundae Paik Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Busan, South Korea
[4] Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Rheumatol, Yangsan, South Korea
关键词
Coronavirus; COVID-19; Pneumonia; Rheumatoid arthritis; Disease-modifying antirheumatic drugs; INFECTIONS;
D O I
10.1007/s00296-020-04584-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [1] Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
    Jehun Song
    Seongmin Kang
    Seung Won Choi
    Kwang Won Seo
    Sunggun Lee
    Min Wook So
    Doo-Ho Lim
    Rheumatology International, 2020, 40 : 991 - 995
  • [2] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [3] Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis
    Feely, Michael G.
    O'Dell, James R.
    CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (03) : 316 - 320
  • [4] Corticosteroids and disease-modifying antirheumatic drugs for coronavirus disease 2019 in patients with rheumatoid arthritis
    Chen, Yu-Han
    Lee, Yuan-Ti
    Ma, Kevin Sheng-Kai
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (07) : 1391 - 1392
  • [5] Effects of the COVID-19 Pandemic in Unvaccinated Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients Using Disease-modifying Antirheumatic Drugs
    Sari, Kemal
    Ozkan, Feyza Unlu
    Aktas, Ilknur
    Akpinar, Pinar
    MEDICAL JOURNAL OF BAKIRKOY, 2023, 19 (02) : 171 - 179
  • [6] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536
  • [7] Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
    Kalyoncu, Umut
    Pehlivan, Yavuz
    Akar, Servet
    Kasifoglu, Timucin
    Kimyon, Gezmis
    Karadag, Omer
    Dalkilic, Ediz
    Ertenli, Ali Ihsan
    Kilic, Levent
    Ersozlu, Duygu
    Bes, Cemal
    Emmungil, Hakan
    Mercan, Ridvan
    Ediboglu, Elif Durak
    Kanitez, Nilufer
    Bilgin, Emre
    Colak, Seda
    Koca, Suleyman Serdar
    Gonullu, Emel
    Kucuksahin, Orhan
    Coskun, Nihan
    Yagiz, Burcu
    Kiraz, Sedat
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (04) : 1615 - 1623
  • [8] COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes
    Haberman, Rebecca H.
    Castillo, Rochelle
    Chen, Alan
    Yan, Di
    Ramirez, Deborah
    Sekar, Vaish
    Lesser, Robert
    Solomon, Gary
    Neimann, Andrea L.
    Blank, Rebecca B.
    Izmirly, Peter
    Webster, Dan E.
    Ogdie, Alexis
    Troxel, Andrea B.
    Adhikari, Samrachana
    Scher, Jose U.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (12) : 1981 - 1989
  • [9] Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis
    Di Munno, O
    Delle Sedie, A
    Rossini, A
    Adamil, S
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (02) : 137 - 144
  • [10] Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis
    Combe, Bernard
    JOINT BONE SPINE, 2006, 73 (06) : 587 - 590